Cardinal Health 2009 Annual Report Download - page 45

Download and view the complete annual report

Please find page 45 of the 2009 Cardinal Health annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 154

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154

Spin-Off and consistent with the Company’s reasons for retaining such shares, but in no event later than five
years after the Spin-Off. As a result, the Company may be required to sell some or all of its retained shares of
CareFusion common stock at a time when it might not otherwise choose to do so. Furthermore, any such
disposition by the Company of its shares of CareFusion common stock in the public market, or the perception
that such dispositions could occur, could adversely affect prevailing market prices for CareFusion common stock
and adversely affect the value or the terms and conditions of such disposition. The Company currently intends to
dispose of its shares of CareFusion common stock in an orderly fashion, but it is not obligated to do so.
Item 1B: Unresolved Staff Comments
Not applicable.
Item 2: Properties
In the United States, the Company has 24 pharmaceutical distribution facilities, four specialty distribution
facilities, 167 nuclear pharmacy laboratory, manufacturing and distribution facilities, and 50 medical-surgical
distribution and assembly facilities utilized by its Healthcare Supply Chain Services segment. In its Clinical and
Medical Products segment, the Company has 22 assembly, medical-surgical manufacturing, and research
operation facilities. The Company’s U.S. operating facilities are located in 45 states and in Puerto Rico.
Outside of the United States, the Company owns or leases two operating facilities in the United Kingdom
and eight operating facilities in Canada and Mexico through its Healthcare Supply Chain Services segment. The
Company owns or leases 21 manufacturing, distribution and research operating facilities in Australia, Canada,
the Dominican Republic, France, Germany, Ireland, Italy, Malaysia, Malta, Mexico, Thailand and the United
Kingdom through its Clinical and Medical Products segment.
The Company owns 76 of its operating facilities, and the remaining 222 operating facilities are leased. The
Company owns the four-story building where its principal executive offices are headquartered, which is located
at 7000 Cardinal Place in Dublin, Ohio.
The Company considers its operating properties to be in satisfactory condition and adequate to meet its
present needs. The Company regularly evaluates its operating properties, however, and may make further
additions, improvements and consolidations as it continues to seek opportunities to expand its role as a provider
of products and services to the healthcare industry.
For additional financial information regarding the Company’s facilities, see Notes 12 and 19 of “Notes to
Consolidated Financial Statements.”
Item 3: Legal Proceedings
The legal proceedings described in Note 11 of “Notes to Consolidated Financial Statements” are
incorporated in this “Item 3—Legal Proceedings” by reference.
Item 4: Submission of Matters to a Vote of Security Holders
Special Meeting of Shareholders
A Special Meeting of Shareholders of the Company was held on June 23, 2009.
23